THE MALAYSIA Healthcare Travel Council (MHTC) applauds the government’s decision to reopen Malaysia’s borders to all travellers from Apr 1, 2022,. It sees it as a positive sign for the recovery of Malaysia’s healthcare travel industry in step with revitalising the nation’s economy.
Marching towards endemicity, MHTC stands guided by the well-detailed plan and guidance announced by the Minister of Health Khairy Jamaluddin.
This timely announcement allows the Council to step up its efforts in the industry’s recovery phase, furthering its goal of providing the best Malaysia healthcare travel experience by 2025.
The full reopening of the borders will allow international patients to have seamless continuity of care and access to world-class quality, accessible, and affordable healthcare services.
Khairy also endorsed the MHTC’s 2022 strategies and plans. The strategies and initiatives are anchored upon the Malaysia Healthcare Travel Industry Blueprint 2021-2025, launched on Nov 1, 2021, by him, will be implemented in two main phases:
i. Recovery Phase (2021-2022) – to reinforce awareness on Malaysia Healthcare’s world-class quality offerings and enhance the patient experience through digitalisation of key touchpoints, creation of more strategic partnerships, unified branding efforts, and raising Malaysian global icons for healthcare.
ii. Rebuild Phase (2023-2025) – industry players collectively work together to amplify awareness of Malaysia Healthcare’s niche offerings, such as the Fertility Hub of Asia, Cardiology Hub of Asia and the Cancer Care Centre of Excellence.
“We look forward to welcoming international travellers back to Malaysia, a safe and trusted destination, strengthened by our nation’s commitment to embracing endemicity,” Mohd Daud Mohd Arif, CEO of MHTC commented.

Mohd Arif
MHTC will continue to intensify its effort to showcase Malaysia Healthcare’s capabilities and strengths by solidifying its position as the Fertility and Cardiology Hub of Asia, Cancer Care Centre of Excellence, as well as the Hepatitis C Treatment Hub of Asia, among others via synergistic Public-Private Partnerships and pave the way for more innovative industry service offerings.